View Older Stories View More Recent Stories

Nov 22, 2016 07:00AM New KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology
Nov 14, 2016 07:14AM OpGen (OPGN), Merck (MRK) Enter Rapid Diagnostics, IT Products Development Collaboration
Nov 14, 2016 06:52AM Merck (MRK) Announces Upcoming Presentation of Strong ZEPATIER Data in Certain HCV Genotypes
Nov 14, 2016 06:30AM Merck (MRK) Announces Significant Data from KEYTRUDA in Adv. Bladder Cancer
Nov 14, 2016 06:29AM Merck (MRK) Presents Results from Three MK-3682B Phase 2s; High SVR Rates Noted
Nov 13, 2016 08:00AM Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Nov 12, 2016 11:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
Nov 12, 2016 08:00AM Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting®
Nov 7, 2016 07:07AM Merck (MRK) Announces New KEYTRUDA Data to be Presented at SITC 2016 Annual Meeting
Nov 7, 2016 07:00AM New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
Nov 2, 2016 04:30PM Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
Oct 31, 2016 03:00AM European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Oct 26, 2016 08:00AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ID Week 2016
Oct 25, 2016 06:45AM Merck Announces Third-Quarter 2016 Financial Results
Oct 24, 2016 06:04PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More)
Oct 21, 2016 09:57PM FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of
Oct 21, 2016 06:50AM Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped Early
Oct 21, 2016 06:45AM Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
Oct 20, 2016 07:32AM Advaxis (ADXS) Commences KEYNOTE-046 Phase B with Merck (MRK)
Oct 19, 2016 07:05AM Merck (MRK) Announces Letermovir Phase 3 Met Primary Endpoint in Bone Marrow Transplant Patients
Oct 19, 2016 07:00AM Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary E
Oct 17, 2016 05:00PM Merck Research Laboratories Facilities Designated as “Milestones in Microbiology” Sites by the American Society for Microbiology
Oct 14, 2016 08:30AM Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community
Oct 10, 2016 09:17AM Pre-Open Stock Movers 10/10: (IPCI) (TSRO) (MYL) Higher; (TWTR) (BMY) (DOV) Lower (more...)
Oct 10, 2016 06:35AM Pfizer (PFE) Presents Encouraging New Data for INLYTA Combo Phase 1b in Adv. RCC
Oct 10, 2016 06:27AM Merck (MRK) Announces Strong KEYTRUDA Data in NSCLC at ESMO 2016; Superior OS Noted
Oct 9, 2016 02:16AM Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell L
Oct 9, 2016 02:15AM KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to
Oct 8, 2016 08:45AM Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
Oct 8, 2016 02:15AM New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients
Oct 7, 2016 04:06PM Merck Animal Health (MRK) Receives USDA Approval of Canine Flu Bivalent Vaccine
Oct 7, 2016 04:05PM Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine
Oct 7, 2016 05:40AM Incyte (INCY) Issues Updates on Epacadostat + Keytruda Phase 1; Says Median PFS Not Reached (MRK)
Oct 3, 2016 08:00AM Merck to Present New Data on ZEPATIER™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016
Sep 29, 2016 01:06PM Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness
Sep 28, 2016 06:46AM Merck (MRK) Says Extensive KEYTRUDA Data Accepted for Presentation at ESMO
Sep 28, 2016 06:45AM Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented
Sep 28, 2016 06:16AM Incyte (INCY) Announces Publication of Updated Phase 1 Data on Epacadostat + Keytruda in Advanced Melanoma (MRK)
Sep 23, 2016 08:00AM Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25
Sep 20, 2016 08:30AM Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights
Sep 15, 2016 08:33AM Pfizer (PFE), Merck (MRK) Announce Ertugliflozin Phase 3 Met Primary Endpoint in T2D
Sep 15, 2016 08:31AM Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Sep 13, 2016 09:00AM Merck Publishes 2015/2016 Global Corporate Responsibility Report
Sep 9, 2016 08:00AM Merck to Participate at the Morgan Stanley Global Healthcare Conference
Sep 7, 2016 06:49AM Merck (MRK) Announces FDA Accepts BLA with Priority Review and Grants Breakthrough Therapy Designation for KEYTRUDA for NSCLC
Sep 7, 2016 06:48AM Merck's (MRK) KEYTRUDA sBLA in NSCLC Accepted for FDA Priority Review
Sep 7, 2016 06:45AM FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients
Sep 2, 2016 07:01AM Merck (MRK) to Discontinue Development of Odanacatib for Osteoporosis
Sep 2, 2016 07:00AM Merck Provides Update on Odanacatib Development Program
Aug 8, 2016 05:06PM Merck (MRK) Announces Publication of Strong ZEPATIER Phase 3 Data as HCV Treatment
View More Recent Stories View Older Stories